AI Analysis | Feedback

Here are 1-3 brief analogies for Shuttle Pharmaceuticals (SHPH):

1. Think of them as a highly specialized biotech startup, like a niche oncology division within a major pharmaceutical company such as Amgen or Gilead Sciences, but exclusively focused on developing drugs that enhance cancer radiation therapy.
2. They're developing 'performance enhancers' for radiation therapy. Imagine an 'Intel for cancer treatment', creating pharmacological 'upgrades' to make existing radiation far more effective and precise.
3. An early-stage Moderna or BioNTech, but instead of developing vaccines, Shuttle is pioneering new drugs to supercharge radiation therapy for cancer patients.

AI Analysis | Feedback

• Ropidoxuridine: A lead clinical-stage radiation sensitizer drug candidate designed to improve the effectiveness of radiation therapy in rapidly growing cancer cells.
• Selective HDAC Inhibitors: A platform of preclinical drug candidates, including SP-2-225, intended to sensitize cancer cells to radiation therapy and stimulate the immune system.

AI Analysis | Feedback

Based on the provided background information, Shuttle Pharmaceuticals (SHPH) is a discovery and development stage company. The company explicitly states:

• "We currently have no FDA approved products and we have not yet applied for a new drug application."
• "We have no product revenue..."

Therefore, Shuttle Pharmaceuticals does not currently have any major customers for products or services. Its funding to date has come from investments from private investors and government contracts obtained from the National Institutes of Health (NIH) for performing research and development.

AI Analysis | Feedback

null

AI Analysis | Feedback

Anatoly Dritschilo, M.D., Chairman & Chief Executive Officer

Dr. Dritschilo is a co-founder of Shuttle Pharmaceuticals, established in 2012, and has served as Chairman and Chief Executive Officer since the company's formation. A radiation oncologist by training, he previously held significant leadership roles at Georgetown University Medical School, including Department Chair from 1980 to 2018, and Chief of Radiation Oncology at MedStar-Georgetown University Hospital. His experience in the pharmaceutical industry includes board membership at NeoPharm, Inc., and he was a founding director of Oncomed (Neopharm). He is also the CEO of Prostate Theranostics, Inc.

Christopher Cooper, Interim Chief Executive Officer

Mr. Cooper was appointed Interim Co-Chief Executive Officer in March 2025 and subsequently continued as Interim Chief Executive Officer. He is also the President, CEO, and Founder of First Towers & Fiber Corp., a telecommunications infrastructure company operating in Latin America, a role he has held since 2017. With over 27 years of experience in management and finance, he has worked in the oil and gas, telecommunications, and technology sectors. From 2010 to 2017, Mr. Cooper served as President and CEO of Aroway Energy, Inc., an oil and gas company where he managed operations, financial reporting, and oversaw acquisitions and financing. Between 1998 and 2010, he acted as a Corporate Consultant for various technology and resources companies, overseeing restructuring activities for distressed public companies and raising over $100 million in debt and equity for clients.

Yuying Liang, CPA, Chief Financial Officer

Ms. Liang was appointed Chief Financial Officer in January 2026, succeeding Chris Cooper in the role. She is a certified public accountant with extensive experience in corporate accounting and financial reporting. Ms. Liang currently serves as CFO for several other companies, including BlockchainK2 Corp., Goldhills Holding Ltd, Intact Gold Corp., Kincora Copper Limited, Transatlantic Mining Corp., Ultra Brands Ltd., Modern Plant Based Foods Inc., and Montego Resources Inc.

Dr. J. Cheol Chang, Chief Scientific Officer for Biology

Dr. Chang serves as the Chief Scientific Officer for Biology at Shuttle Pharmaceuticals. Detailed professional background information specifically for Dr. J. Cheol Chang in this role is not readily available in the provided sources. Historically, the Chief Scientific Officer for Biology role, including being a co-founder of the company, and a tenured Professor of Radiation Medicine and Microbiology at Georgetown University Medical School with over 30 years of experience in molecular radiation biology, was held by Dr. Mira Jung until 2019.

Dr. Tyvin A. Rich, M.D., Chief Medical Officer, Chief Clinical Officer

Dr. Rich serves as Shuttle Pharmaceuticals’ Chief Medical Officer and is responsible for the clinical development of novel radiation sensitizers. Since 2010, he has been a Staff Radiation Oncologist at the Hampton University Proton Therapy Institute in Hampton, Virginia, and a Professor Emeritus at the University of Virginia Health Sciences Center, Department of Radiation Oncology. Prior to that, from 1995 to 2010, Dr. Rich was a Professor and Chairman of the Department of Therapeutic Radiology and Oncology at the University of Virginia Health Sciences Center. He also served as a Professor of Radiotherapy and Director of Clinics in the Department of Radiotherapy of the University of Texas M. D. Anderson Cancer Center from 1984 through 1995. He has authored more than 200 scientific articles, reviews, and book chapters.

AI Analysis | Feedback

Key Risks to the Business

The most significant risk to Shuttle Pharmaceuticals is its **ability to continue as a going concern**. The company has no product revenue and relies solely on investments from private investors and government contracts from the National Institutes of Health (NIH) for funding. Its independent auditors expressed doubt about the company's ability to continue operations in their report dated June 3, 2022. This fundamental risk encompasses the challenges of securing sufficient future funding to sustain operations and advance its drug candidates.

A second key risk is the **inherent uncertainty and high failure rate associated with pharmaceutical development and regulatory approval**. As a discovery and development-stage company, Shuttle Pharmaceuticals currently has no FDA-approved products and has not yet applied for a new drug application. Its lead drug candidate, Ropidoxuridine, has only completed a Phase I clinical trial, while its HDAC inhibitor platform drug candidates are still in preclinical models. The process of drug development is lengthy, costly, and has a high probability of failure at various stages of clinical trials, which could prevent the company from ever bringing a product to market or generating revenue.

AI Analysis | Feedback

null

AI Analysis | Feedback

AI Analysis | Feedback

For Shuttle Pharmaceuticals (SHPH), expected drivers of future revenue growth over the next 2-3 years include:

1. Advancement of Ropidoxuridine through subsequent clinical trial phases: Shuttle Pharmaceuticals' lead clinical sensitizer drug candidate, Ropidoxuridine, has completed a Phase I clinical trial. Progressing this candidate into and through Phase II and potentially Phase III clinical trials would be a significant step, increasing the drug's value and the company's attractiveness for partnerships or eventual market launch.
2. Initiation of clinical development for the HDAC inhibitor platform: The company's selective histone deacetylase (HDAC) inhibitors have been tested in preclinical models. Advancing these candidates into human clinical trials would expand Shuttle Pharmaceuticals' pipeline, creating additional avenues for future revenue generation and demonstrating the potential of their technology platform.
3. Successful acquisition of further non-dilutive government grants and contracts: Shuttle Pharmaceuticals has historically been funded by government contracts, such as Small Business Innovation Research (SBIR) contracts from the National Institutes of Health (NIH). Securing additional Phase II SBIR funding for projects like "Cell-based Models for Prostate Cancer Health Disparity Research" and "Predictive Biomarkers of Prostate Cancer Sensitivity for Radiation Late Effects" would provide crucial funding for ongoing research and development without diluting equity.
4. Formation of strategic partnerships or licensing agreements: As a discovery and development stage company with no current product revenue, establishing collaborations or licensing agreements with larger pharmaceutical companies for its drug candidates (Ropidoxuridine or the HDAC inhibitors) could generate significant upfront payments, milestone payments, and future royalties, providing substantial revenue well before any potential product launch.

AI Analysis | Feedback

Share Issuance

• In August 2022, Shuttle Pharmaceuticals completed its Initial Public Offering (IPO), raising gross proceeds of $9,960,340 through the issuance of 1,225,888 units of common stock and warrants.
• In March 2025, the company conducted an underwritten public offering of 19,166,667 shares of common stock (or pre-funded warrants), generating approximately $5.75 million in gross proceeds. The net proceeds from this offering were intended to fund a Phase II clinical trial, marketing, and general corporate purposes.
• In March 2026, Shuttle Pharmaceuticals announced a public offering with an expected gross proceeds of approximately $3.5 million from the issuance of 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares. Up to $1.5 million of the net proceeds are designated for marketing efforts, with the remainder for working capital and general corporate purposes.

Inbound Investments

• Shuttle Pharmaceuticals has historically received funding from private investors and government contracts, specifically Small Business Innovation Research (SBIR) contracts from the National Institutes of Health (NIH), to support its research activities.
• Beyond the IPO, the company continued to secure capital from investors through various public offerings and private placements to fund its operations and development.

Outbound Investments

• In November 2025, Shuttle Pharmaceuticals acquired the AI Health Platform, Molecule.ai, which involved a cash payment of $3.0 million at closing and the assumption of $6.4 million in future payment obligations.